Klínískar rannsóknir á góðkynja einstofna mótefnahækkun, með áherslu á fylgikvilla og horfur - verkefni lokið
Fréttatilkynning verkefnisstjóra
Multiple myeloma (MM) is an incurable B-cell malignancy, and is always preceded by a monoclonal gammopathy of undetermined significance (MGUS), where patients have an M-protein on electrophoresis, but no sign of a malignant disorder. In this project we evaluated several important aspects in MGUS, with focus on complications and prognosis.
Approximately 5% of people over the age of 60 years have MGUS, which makes it very attractive as a research tool to increase our understanding of MM and related diseases. As MGUS is by definition asymptomatic, most previous MGUS studies have been based on clinical cohorts of MGUS patients, which are subject to bias. Cross-sectional studies are ideal for evaluating MGUS complications.
We screened for MGUS in all individuals from the AGES-Reykjavik study, a longitudinal cohort study of 5,764 individuals born 1907-1934 in Iceland. We identified several new findings highlighting the importance of MGUS with regards to overall prognosis as well as its impact on cardiovascular, profile, bone disease, and malignant progression in MGUS. These results resulted in a nationwide screening study in Iceland where all individuals in Iceland born 1975 and before are invited, a total of over 148,000 individuals.
Heiti
verkefnis: Klínískar rannsóknir á góðkynja einstofna mótefnahækkun, með áherslu
á fylgikvilla og horfur
Verkefnisstjóri: Sigurður Yngvi Kristinsson, Háskóla Íslands
Tegund styrks: Verkefnisstyrkur
Styrktímabil: 2013-2015
Fjárhæð styrks: 19,09
millj. kr. alls
Tilvísunarnúmer
Rannís: 130342
